Since previous work related ENTPD5 levels to prostate cancer survival [4, 21], compounds 1a, 1b (as control), and 2f were assayed with prostate cancer cell line LNCaP to determine their effect on cell proliferation. Here, ENTPD5 is linked to prostate carcinoma.